ARCHIVES

New Agents, New Approaches Benefit Treatment Of Advanced Lung Cancer

This article is from The Cancer Letter archive.

Vol. 26 No. 8 | August 29, 2003

Download PDF Visit The Full Archive

Related Articles

New Phase III Trial Reviews Approve 25%; Should Trialists Worry? Not Yet,

January 19, 2007

ASCO President Swain: “Shattering Impact on Cancer Enterprise”

February 15, 2013

President Sppointed John Niederhuber NCI Director.

September 8, 2006

In Brief: Clarkson, Freireich Head AACR, ASCO; Oncology Nursing Society Membership Total Now 2,369

June 6, 1980

Erin Fox: Shortages to Continue for 4-6 Years

October 11, 2013

FDA News: FDA Eases Two-Trial Standard For Proof Of Drug Efficacy

March 21, 1997